Adverse events of all grade (safety population)
| No. of patients with at least one adverse events | Level dose 1 | Level dose 2 | Total |
| N=13 | N=6 | N=19 | |
| 13 (100%) | 6 (100%) | 19 (100%) | |
| Fatigue | 9 (69%) | 5 (83%) | 14 (74%) |
| Diarrhea | 10 (77%) | 3 (50%) | 13 (68%) |
| Disease-related pain | 9 (69%) | 3 (50%) | 12 (63%) |
| Fever | 7 (54%) | 4 (67%) | 11 (58%) |
| Pain | 8 (62%) | 2 (33%) | 10 (53%) |
| Nausea/vomiting | 7 (54%) | 3 (50%) | 10 (53%) |
| Anorexia | 6 (46%) | 2 (33%) | 8 (42%) |
| Constipation | 4 (31%) | 3 (50%) | 7 (37%) |
| Colitis | 4 (31%) | 2 (33%) | 6 (32%) |
| Pruritus | 4 (31%) | 2 (33%) | 6 (32%) |
| Weight loss | 6 (46%) | 0 (0%) | 6 (32%) |
| Anemia | 2 (15%) | 4 (67%) | 6 (32%) |
| Edema of limbs | 4 (31%) | 1 (17%) | 5 (26%) |
| Dyspnea | 3 (23%) | 2 (33%) | 5 (26%) |
| Skin eruption | 3 (23%) | 1 (17%) | 4 (21%) |
| Vitiligo | 4 (31%) | 0 (0%) | 4 (21%) |
| Hypereosinophilia | 3 (23%) | 1 (17%) | 4 (21%) |
| Alanine/aspartate aminotransferase increased | 2 (15%) | 2 (33%) | 4 (21%) |
| Cough | 3 (23%) | 1 (17%) | 4 (21%) |
| Lymphedema | 3 (23%) | 1 (17%) | 4 (21%) |